Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Bupivacaine is a local anesthetic used in a wide variety of superficial and invasive procedures. A painkiller injection used for the management of pain during medical or dental procedures.
- Mechanism
- Curator reviewed · 8 references
Like lidocaine, bupivacaine is an amide local anesthetic that provides local anesthesia through blockade of nerve impulse generation and conduction.[L30533 ] These impulses, also known as action potentials, critically depend on membrane depolarization produced by the influx of sodium ions into the neuron through voltage-gated sodium channels. Bupivacaine crosses the neuronal membrane and exerts its anesthetic action through blockade of these channels at the intracellular portion of their pore-forming transmembrane segments. The block is use-dependent, where repetitive or prolonged depolarization increases sodium channel blockade. Without sodium ions passing through the channel’s pore, bupivacaine stabilizes the membrane at rest and therefore prevents neurotransmission.
In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.
While it is well-established that the main action of bupivacaine is through sodium channel block, additional analgesic effects of bupivacaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia.
- Primary indication
- As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.Curator reviewed · 76 structured indications
- Formula / weight
- C18H28N2O · 288.4277 g/mol (avg)
- First approval
- Canada, 2004 · United States, 1988 · European Union, 2020
- Also known as
- Bupivacain · Bupivicaine · DL-Bupivacaine · Racemic bupivacaine
- Code names
- AH 250 · DUR-843 · LAC-43 · SKY-0402 · Win 11318
Resolves to
LEBVLXFERQHONN-UHFFFAOYSA-NSMILESCCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Bupivacaine, and which of those have an active Phase 3 trial?